Tempus AI, Inc.
Tempus (Nasdaq: TEM) is a healthcare technology company that combines diagnostic testing, clinical data and artificial intelligence to support personalized care and therapeutic research. Its two product lines are Diagnostics, which provides next-generation sequencing, PCR profiling and other pathology tests, and Data… From the company’s description.
In fiscal 2025, Tempus AI, Inc. reported revenue of $1.27B, up 83.4% from fiscal 2024, and a net loss of $245.03M. Its operating margin was −19.9%, and operations used $218.09M in cash. Over the twelve months to Jun 30, 2026, revenue was $1.43B.
Margins and return on equity change in ; everything else in percent. Fewer shares and less debt are shown plainly, not as bad news — it depends what you make of buybacks. Dotted labels explain each measure. is shown separately from the annual figures.
What Tempus AI, Inc. does
In the company’s own words
Tempus (Nasdaq: TEM) is a healthcare technology company that combines diagnostic testing, clinical data and artificial intelligence to support personalized care and therapeutic research. Its two product lines are Diagnostics, which provides next-generation sequencing, PCR profiling and other pathology tests, and Data and applications, which offers de-identified data, analytics, clinical-trial support and AI tools to healthcare providers and life sciences companies. Diagnostics includes oncology and hereditary testing, while Data and applications includes products such as Insights, Trials, Next and Algos. The company’s software also helps physicians order tests, review results and identify clinical trials, and enables researchers to analyze patient cohorts. Tempus connects with more than 5,000 healthcare institution sites through approximately 700 data connections. As of December 31, 2025, its database included more than 8.6 million de-identified patient records. Its business expanded beyond oncology through the 2025 acquisitions of hereditary-testing company Ambry Genetics and pharmacogenomics company OneOme.
Company details
- Sector
- Health Care
- Industry (SIC)
- Computer Services
- Headquarters
- CHICAGO, IL
- Fiscal year end
- December
- CIK
- 1717115
- SIC
- 7370
Financial performance, year by year
Fiscal 2024–2025 · USDThe full income statement, balance sheet and cash flow for each of these years — every figure traceable to its filing — is on the Financials tab with a free account.
Who owns Tempus AI, Inc. — and what changed
Funds as of 2026Q2 · superinvestors as of 2026-06-30
Largest fund holders · Tempus AI, Inc.’s weight in each
Fund ownership is a floor, not a census — pensions, insurers and people holding shares directly are not visible here.
Tempus AI, Inc.’s bonds, as funds hold them
Funds report holding 2 issues of Tempus AI, Inc.’s debt, $117.59M at market value — what funds hold, not the company’s total debt. Weighted-average coupon 0.75%, maturing 2030 to 2032.
Fund ownership counts N-PORT filers only, so it is a floor rather than a census — pensions, insurers and direct holders are not visible here, and the remainder is not “held by individuals”.
Every fund and institutional holder, quarter by quarter, is on the Ownership tab with a free account.
Recent filings
All filings →Each filing opens into its own statements and disclosures here.
Put this business in context.
Compare this company with peers, find it in your funds and follow its financial history with your connected AI:
- “How do Tempus AI, Inc. and its peers compare on margins and cash generation over ten years?”
- “Where did five years of Tempus AI, Inc.'s earnings go — cash, debt, buybacks, reinvestment?”
- “What changed in Tempus AI, Inc.'s last four quarterly filings that the numbers alone won't show?”